Anuncia Medical Inc. Announces Published Data with Promising Clinical Outcomes Using the ReFlow™ Ventricular System In-Line with Hydrocephalus Shunts

SCOTTSDALE, Ariz., May 23, 2023 /PRNewswire/ — Anuncia Medical Inc. (“Anuncia” or the “Company”), a company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce that an article highlighting its FDA cleared and CE Marked ReFlow™ Ventricular System “Gen 1” with Hydrocephalus shunts in patients suffering from chronic shunt occlusions, has been published in Pediatric Neurosurgery. Two years prior to being implanted with the ReFlow™ System, 7 of the 9 patients represented in the publication experienced a combined total of 14 proximal shunt failures that required revision. In the 2-4 years following ReFlow™ implantation and use to maintain flow, only 1 proximal shunt failure occurred amongst the 9 patients. As revisions are typically associated with expensive hospital admissions for both the child and family, reducing the number of revisions needed is invaluable to those impacted.Continue reading

Atlanta Nonprofit, Purple Pansies, Donates $726,000 in Support of TGen Clinical Study

PHOENIX, ARIZONA — MAY 23, 2023 — A $726,000 donation from Atlanta-based charity Purple Pansies will support a TGen-led clinical trial designed to increase a patient’s unfolded protein response (UPR) to push the cancer cells to reach a state of programmed cell death. UPR is a cellular defense mechanism that, when triggered, sends signals to the cell’s nucleus to restore balance and ensure that proteins are folded properly, which is essential for normal cell function.Continue reading

Xcellerant and Flinn Foundation Partner to Fuel Growth in Arizona Bioscience and Healthcare Sectors

SCOTTSDALE, Ariz–(BUSINESS WIRE)–Xcellerant Ventures (XVC) welcomes the Flinn Foundation as a limited partner in its Xcellerant Venture Capital Fund I. Xcellerant Ventures is a venture capital firm investing in early and seed stage startups within the HealthTech and MedTech sectors. Xcellerant seeks to invest in dynamic founding teams with strong intellectual property portfolios that XVC believes will transform medical practice and dramatically improve healthcare.

Continue reading

GT Medical Technologies Marks a Significant Milestone: The 1,000th Order for GammaTile® Therapy

TEMPE, Ariz.May 18, 2023 /PRNewswire/ — GT Medical Technologies, Inc. announced receipt of the 1,000th order for GammaTile Therapy.

Driven to overcome the limitations of current treatments for brain tumors and improve the standard of care, a team of brain tumor specialists joined forces to form GT Medical Technologies, Inc. GammaTile Surgically Targeted Radiation Therapy (STaRT) is the newest option for patients undergoing brain tumor resection. Continue reading

HonorHealth Research Institute collaborator Worldwide Clinical Trials expands Site Alliance Collaboration to support oncology trials

RESEARCHTRIANGLE PARK, N.C. and SCOTTSDALE, ARIZ. – In response to the growing and ever-changing clinical research landscape and the need to bring innovative treatments to patients faster, Worldwide Clinical Trials (Worldwide), a leading global, full-service contract research organization (CRO), has expanded its Site Alliance Collaboration with new partners across the United States and Europe.Continue reading